Good post bro... you and
@Rykster put that one together?
Cash Run Away scenarios
❌ No new funding 0.26 months
✅ A$5.0M via placement, Only = 6.8 months
✅ Launched a A$10.8M entitlement offer Placement + Entitlement = 21.0 months
✅ A$10M R&D advance = 34.2 months
✅ A$8.5M R&D rebate + R&D advance (expected Q4 2025).= 45.4 months (~3.8 years)
the upcoming interim readout from the Phase 3 Diabetic Foot Infection (DFI) trial in Indonesia, expected in Q1 2026, represents a significant near-term catalyst in my view — particularly when backed by the 93% efficacy demonstrated in the recent Phase 2 ABSSSI trial.Yes, Recce’s timelines tend to slip (as is often the case in biotech), but even accounting for that, I believe the company is financially tied over until meaningful news flow emerges.
(20min delay)